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Summary.-Human dialysable Transfer Factor (TFd) extracted from lymphocytes
of patients with transitional cell carcinoma of the bladder (TCCB) was replicated
in culture by lymphoblastoid cell lines. The effectiveness of two such TFdLs pro-
duced in vitro in transferring sensitivity to TCCB was assessed in the lymphocyte
migration test (LMT) using formalin-treated TCCB cells as antigen. The results
showed that one TFdL transferred sensitivity in 5/14 cases and the other in 12/15,
not only to leucocytes of healthy individuals but also to leucocytes of TCCB patients.
Preliminary results showing an in vivo transfer of sensitivity are discussed.
IT has recently been shown that
human dialysable Transfer Factor (TFd)
extracted from peripheral blood lympho-
cytes can be successfully replicated in
culture by lymphoblastoid cell lines (Viza
et al., 1974, 1975) and that such TFd
reproduced in vitro can transfer sensi-
tivity to various non-tumour antigens
such as candidine, PPD and measles
virus (Viza et al., 1975). However, some
of the original data provided by our
collaborators, viz. the use of human or
culture TFd for transfer in rats, which
we have previously reported, has been
challenged as unreproducible by our own
laboratory (Boucheix and Viza, unpub.).
It was thus desirable to investigate
further TFd produced in vitro in order to
discover whether a TFd capable of trans-
ferring sensitivity towards tumour cells
could be replicated in the in vitro cell
culture system.
The existence of cell-mediated im-
munity to transitional-cell carcinoma of
the bladder (TCCB) has already been
demonstrated (Bubenik et al., 1970;
O'Toole et al., 1973; Bloom, Ossorio and
Brosman, 1974). Furthermore, inhibition
ofleucocyte migration in presence of tum-
our extracts (Segall et al., 1972) or whole
tumour cells (Ax and Tautz, 1974) or
formalin-treated tumour cells (Ross et
at., 1973) has also been shown. Formalin-
treated TCCB cells were therefore used
in the Leucocyte Migration Test (LMT)
to assess patients' immune responses.
Since there is a wide range of cross
reactivityinthe bladdertumours (Bubenik
et al., 1970), TFd obtained from patients
whose leucocyte migration was found to
be inhibited in the presence of TCCB
cells was used for in vitro replication.
The effectiveness of the TFd produced in
vitro to transfer TCCB sensitivity to
leucocytes from healthy individuals was
assessed by the LMT.
MATERIAL AND METHODS
Expertmental design.-Leucocytes from
TCCB patients before surgery were tested
in LMT against tumour cells from other
TCCB patients. Patients showing strong
inhibition in the presence of tumour cells
were chosen as donors of TFd for induction
of continuous Lymphoblastoid Cell (LC)
cultures. Leucocytes from individuals notIN VITRO PRODUCTION OF A SPECIFIC TRANSFER FACTOR
sensitized to TCCB cells were incubated
with TFd obtained from these induced cell
lines (TFdL) and the inhibition in the
presence of TCCB cells of these leucocytes
was compared to that observed with the
leucocytes from the same individual prior to
their incubation with TFdL.
Preparation of tumour cells.-Surgically
removed tumours were minced and a cell
suspension was obtained by passage through
a metal mesh. Cells were washed 3 times
with normal saline and they were subse-
quently suspended at room temperature in
a formalin buffer (Ross et al., 1973) for 12 h.
They were afterwards washed 3 times in
normal saline and kept at 4°C. Pooled
leucocytes (PL) from 5 apparently healthy
donors were treated in the same way with
the formalin buffer and used in the controls
to evaluate the specificity of the migration
inhibition by the tumours cells.
Leucocyte Migration Test (LMT).-20 ml
of blood were taken in a heparinized (1000
iu) syringe and mixed with 5 ml of plasmagel
(Roger Bellon, Paris). Thebloodwas allowed
to settle for 60 min and the cells recovered
from the enriched leucocyte fraction after
3 washings in TC 199 medium. They were
subsequently suspended at 6 x 107 cells/ml
and aliquots were mixed at the following
ratios of formalin-treated tumour cells to
leucocytes-1: 25, 1: 50, 1: 100, 1 : 200.
Formalin-treatedPLfromhealthyindividuals
was used at the same ratios. The suspen-
sions ofleucocytes, with or without formalin-
treated cells, were carefully placed in sterile
heparinized capillary tubes (Clay Adams,
75 mm long, 1-1 mm internal diameter) one
extremity of which was fire-sealed. The
capillaries were subsequently centrifuged
for 5 min (150 g) at room temperature and
afterwards cut at the interface between the
cell pellet and the supernatant. The tubes
containing the cell pellets were then placed
in sterile migration chambers filled with
TC 199 medium containing streptomycin,
penicillin and 5% foetal calf serum (FCS)
and incubated for 18 h at 37°C. Projection,
magnifying x20 the leucocyte migration
area, was used to evaluate the test. The
projected area was measured by a planimeter
and the mean value of 3 measures was taken.
The diameters of migration areas were also
measured directly on graph paper. The
migration index (MI) is expressed by the
following ratio:
40
mean leucocyte migration
with TCCB or PL
mean leucocyte migration
without TCCB and PL
The statistical significance of migration
inhibition was calculated using Student's
t test. Arn MI less than or equal to 0580
was considered as positive (Table I). All
tests were performed in duplicate or quadru-
plicate and the mean values taken for the
evaluation of the MI.
In vitro test of transfer of the TCCB
sensitivity by TFdL.-40 ml of blood was
taken from a healthy donor or a patient
with TCCB. Leucocytes were separated
and suspended in RPMI 1640 medium,
supplemented with 10% FCS. An aliquot
was incubated with TFdL for 5 h at 37°C in
a CO2 humidified atmosphere and gently
agitated every hour. TFdL extracted from
107 LC was used for the incubation of 107
lymphocytes. Cells were washed twice at
the end of the incubation with TC 199
medium containing 5% FCS and used
for the LMT as previously described.
A statistical comparison was made be-
tween the MIs of leucocytes in the presence
of TCCB cells (Table II) according to
whether or not the leucocytes had been
previously incubated with TFdL.
TF replication in vitro.-LCs of two
cell lines derived from peripheral blood
lymphocytes of healthy individuals were
used. Both cell lines were grown in RPMI
1640 medium containing 15 mg/l gentamycin
sulphate, and supplemented with 10% FCS,
in static or spinner suspension cultures.
The induction procedure used was as
follows: the cells were suspended in medium
at 4 to 5 x 105 cells/ml and TFd from
5 x 106 lymphocytes after filtration through
a millipore filter (0-22 4m) was added to
TABLE I.-Comparison ofthe Mean Values
±s.d. of the Two Series of Experiments
Showed a P < 0-001. It was thus De-
cided that an MI < 0580 is Significant
and should be Considered as Positive
Mean of MI of 86 LMT tests of 23 0-68±0-12
TCCB patients with mean MI<0
- 80
in the presence of TCCB formalin-
treated cells
Mean of MI of 46 LMT tests of the 0-98±0-09
same 23 patients in presence of PL
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TABLE II.-Migration Indices (MI) of Leucocytes from Patients with Carcinoma of the
Bladder (B.A., F.B., P.G. and P.C.) and Healthy Volunteers (A.E., P.A., P.V. and
I.L.) after Incubation with Various Concentrations of Formalin-treated Tumour Cells
(from Patients B.A., T.G., F.B., T.A., P.C., B.T. and C.R.) and alsoFormalin-treated
Leucocytes from a Pool of Healthy Donors
Incubation with
Leucocyte
donor
Apparently healthy
volunteers
A.E.
P.A.
Tumour
cells
(TC)
B.A.
B.A.
T.G.
B.T.
Pool
T.A.
B.A.
Pool
Ratio
TC: leucocytes
1:100
1: 50
1: 50
1 : 50
1: 50
1 : 50
1: 50
1: 50
TF D24
M.±s.d. P<
MI±s.d. P<
0-84±0-05
0-68±0-05
0 68±0 03
0 84±0 04
0 88±0 02
NT
NT
NT
NS
0 005
0-025
0-02
NS
TF A12
MI±s.d.
NT
NT
NT
NT
NT
0-85±0-03
077±003
0-84±0-04
No TF
-Th
P< MI±s.d.
- 1-02±0-02
1 00±0 00
- 1*06±0-06
- 1-24±0-02
- 1 06±0 06
NS
0 05
NS
0- 94±0- 07
1 000- 02
1-07±0- 07
P.V.
I.L.
TCCB patients
B.A.
F.B.
P.G.
P.C.
B.A.
T.A.
B.A.
C.R.
P.C.
Pool
B.A.
B.A.
T.G.
Pool
F.B.
F.B.
B.A.
B.A.
T.G.
Pool
Pool
P.G.
B.A.
Pool
P.C.
P.C.
B.A.
T.G.
C.R.
Pool
1: 50
1 :50
1: 50
1 :50
1 :50
1 :50
1 : 200
1 : 50
1: 50
1: 50
1: 50
1 :25
1 :50
1 :25
1: 25
1: 50
1 : 25
1 : 100
1 : 25
1 : 25
1: 50
1 : 25
1: 50
1: 50
1: 50
1 :50
NT
NT
0 74+0- 02
0 77±0- 03
0-62±0- 02
0 91±0-03
0-75±0- 03
0-54±0-02
0-58±0-02
0-92±0-11
0-43±0-02
0-43±0- 03
0-71±0- 01
0-71±0-01
0-57±0- 03
1-07±0- 07
1-14±0-04
NT
NT
NT
0-62±0-04
0-19±0-01
1-00±0- 02
0-68±0-06
0-68±0-03
0-94±0-04
0-88±0-06 NS 1-00±0-05
0-77±0-02 0-025 0-96±0-02
0-02
0-02
0-025
NS
0-05
0-05
0-025
NS
0-02
NS
0-02
0-01
NS
NS
NS
NS
0-001
NS
0-05
NS
NS
0-88±0-04
0-91±0-05
1-00±0- 02
1-00±0-04
0-83±0-08
0-75±0 01
0-77±0- 02
1-00±0-10
0-62±0-05
0-50±0- 02
0-83±0-03
0-81±0-01
0-75±0- 02
1-00±0-05
1-00±0-05
NS
NS
NS
NS
NS
0-05
0-02
NS
NS
NS
NS
NS
NS
NS
NS
0-80±0-05 NS
0-64±0-01 0-02
0-90±0-02 NS
NT -
NT
NT
NT
NT
NT
1-00±0- 02
1-04±0- 02
0-96±0-04
1-02±0- 02
1-05±0-05
1-10±0- 06
0-95±0-05
1-25±0- 05
0-71±0-03
0-43±0- 03
1-14±0-06
0-86±0-01
0-57±0- 03
1-05±0-05
1-00±0- 02
1-00±0- 02
0-77±0-01
0-83±0-01
0*50±0-01
0-44±0-01
1-00±0- 02
1-00±0- 02
0-75±0- 03
1-00±0-02
Aliquots were incubated with TFdL D24 or A12, whereas controls were not incubated with TFdL. It
is worth noting that transfer of sensitivity was observed in most cases, and when an inhibition was already
present prior to the incubation with TFdL, it was increased after TFdL incubation, with the exception
of 3 cases. The s.d. was calculated for the MI of each experiment and the P value was obtained by com-
paring the mean ±s.d. of the MI after TF incubation to the mean ±s.d. of the MI of the same cells without
TF incubation.
NT: Not tested.
NS: Not significant (P > 0-05).
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100 ml of tissue culture. In this set of
experiments a single induction with TFd
was used. After this addition of TFd, the
cells were grown for extraction by the
addition of fresh medium as required.
Samples of approximately 108 cells were
taken each week for 4 to 5 weeks and
harvested by centrifugation (250 g for 10
min.); dialysate was obtained by the same
technique used to prepare TFd (Lawrence,
1974). LC not incubated with TFd was
also grown, harvested and extracted in
the same way. The dialysate thus obtained
was used as control and it is designated as
Lymphoblastoid Cell Dialysate (LCD).
RESULTS
Leucocytes from 4 healthy donors
and 4 patients with TCCB were tested
in LMT against formalin-treated TCCB
cells before and after incubation with
2 different TFdL preparations. Formalin-
treated TCCB cells from 7 patients
(B.A., T.G., P.G., F.B., T.A., C.R. and
P.C.) were used for these tests (Table II).
It should be noted that the cells from
P.G. and F.B. were used only in auto-
logous situations, whereas cells from B.A.
P.C. and C.R. were used in both auto-
logous and allogeneic tests. All leuco-
cytes were tested with at least 2 TCCB
cell preparations before and after TFdL
incubation. Two different TFdLs were
used: TFdL A12 and TFdL D24.
TFdL A12 was the product ofinduction
of cell line 43912 (Bechet et al., 1972)
with TFd from a patient whose leuco-
cytes were found reactive to TCCB cells
from the tumour of patient T.A. TFdL
D24 was produced by induction of cell
line B.F. with TFd from a patient whose
lymphocytes were found reactive to tu-
mour cells of patient B.A. and unreactive
to T.A. tumour cells.
The results summarized in Table II
show that TFdL A12 transferred reac-
tivity in 5/14 cases and TFdL D24
transferred reactivity in 12/15 cases.
In the autologous situation, i.e. when
the patient's leucocytes were tested with
his own tumour cells, transfer was ob-
tained with patients B.A. and P.C. using
TFdL D24, and with patients B.A. and
P.G. using TFdL A12; the existing
reactivity of patient F.B. was increased.
LCD from the uninduced B.F. line
used under the same circumstances with
the leucocytes of 4 of the TCCB patients
who had already shown inhibition when
treated with a TFdL preparation, did
not increase leucocyte inhibition in the
presence of TCCB cells.
Further controls of the specificity
of TFdL were performed. It was thus
shown that TFdL A12 or D24 did not
transfer any reactivity against formalin-
treated cells obtained from 3 melanoma
cell lines (Mel-SKI, IGRI, IGR3) and
3 hypernephromata.
Furthermore when cell line B.F. was
induced with TFd obtained from patients
with hypernephroma or adenocarcinoma
of the colon, whose leucocytes had shown
reactivity when tested against autologous
or homologous tumour cells, the TFdL
thus derived failed to sensitize leucocytes
obtained from two healthy volunteers
tested against formalin-treated TCCB
cells.
DISCUSSION
It has been shown in our laboratory
that certain lymphoblastoid cell lines
can reproduce TFd extracted from peri-
pheral blood lymphocytes (Viza et al.,
1974, 1975). Reactivity to antigens such
as PPD, candidine and measles virus
can be transferred by this tissue culture
TFdL. It is worth noting that although
human TFd does not sensitize rats in
our hands, as we have already stated in
the introduction of this publication, a
recent report by some of the co-investiga-
tors, whose results claiming a transfer in
rats were reported in the very first
publication showing TFdL production
(Viza et al., 1975), insists that such a
sensitization is possible (Goust, Welch
and Fudenberg, 1975). The question
therefore remains entirely open. The
present series of experiments shows that
LC can be induced to reproduce TFd
from cancer patients sensitized to tumour
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antigens and this tissue culture TFdL can
transfer the tumour sensitivity to non-
sensitized leucocytes.
In order to confirm that the dialysate
obtained from uninduced LC does not
contain any immunological activity, trans-
fer experiments with this dialysate were
carried out and they failed to show
inhibition in the LMT, whilst the TFdL
producedfrom the same cellswaseffective.
The absence of inhibition in the
LMT, in which hypernephroma or melan-
oma cells were used as antigens, when a
TFdL for TCCB was used for the incuba-
tion, suggests the specificity of the TFdL
produced in vitro. Similarly, the failure
of TFdL induced by TFd from non-TCCB
cancer patients to sensitize leucocytes
to TCCB cells, also indicates specificity
of the TFdL. However, the controversy
over the specificity transferred bv TFd
is not settled and it must be emphasized
that the purpose of the present report is
not to conclude this problem, but merely
to show that TFdL after a successful
induction behaves in a similar fashion
to the TFd used for its production.
Nevertheless, it must be admitted that
the results obtained are in favour of the
specificity of TFd. Further work along
these lines using specific TFdL for
well-defined, non-tumour antigens, is
currently in process and should provide
a definite answer.
TFdL was found to transfer reactivity
against tumour cells not only to leuco-
cytes from healthy individuals but also
to the leucocytes of TCCB-unreactive
patients. In 3 cases (B.A., P.G. and
P.C.), patients' leucocytes unreactive to
autologous tumour cells prior to TFdL
incubation were found reactive after-
wards. In a fourth patient (F.B.) the
reactivity was increased after TFdL in-
cubation (Table II).
SinceTFdhasalreadybeensuccessfully
used for therapy of cancer patients (for
recent reviews see Lo Buglio and Neid-
hart, 1974; Levin et al., 1975; Lawrence,
1974), it is plausible to suppose that in
the near future it will be advantageously
replaced by TFdL as the latter proved
the transfer of sensitivity to tumour
cells in vitro (Pizza et al., 1975). Indeed,
the main restriction of TFd therapy is
obtaining large quantities of a TFd
with known activity. There are no such
limitations for TFdL produced in culture,
which can be tested and standardized
prior to use.
In the light of the results described
here, it seems important for injection of
patients to use TFdL capable of sensitiz-
ing the patient's leucocytes to the auto-
logous tumour cells now that this can
be assessed by the in vitro tests. Pre-
liminary results with 3 patients have
already shown that TFdL injection trans-
ferred the tumour reactivity in vivo and
the patient's leucocytes became reactive
to the autologous and allogeneic tumour
cells in the LMT 4 days after the second
injection, using TFdL from 108 cells
per injection. This reactivity persisted
for 6 weeks without further injections.
In vitro tests performed prior to the
TFdL injection had shown that the
patient's leucocytes could be rendered
reactive to the autologous TCCB cells
by the same TFdL used for the subsequent
injection of the patient. Further studies
aiming for long-term clinical trials with
TFdL are now in progress.
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